October 03, 2021
Long-acting pre-exposure prophylaxis (PrEP) is not only a long sought-after measure of HIV control in the infectious disease community—it’s a now tangible opportunity that would alter both diagnostics and care. In an interview with Contagion during IDWeek 2021, Raphael J. Landovitz, MD, MSc, of the UCLA Center for Clinical AIDS Research & Education, reviewed his own presentation on the current status and promising developments of long-acting PrEP... Full news release on www.contagionlive.com
